Helen Wei

2.4k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Helen Wei is a scholar working on Pathology and Forensic Medicine, Hematology and Genetics. According to data from OpenAlex, Helen Wei has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 8 papers in Hematology and 6 papers in Genetics. Recurrent topics in Helen Wei's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Traumatic Brain Injury and Neurovascular Disturbances (5 papers). Helen Wei is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Traumatic Brain Injury and Neurovascular Disturbances (5 papers). Helen Wei collaborates with scholars based in United States, Japan and Poland. Helen Wei's co-authors include Maiken Nedergaard, Hongyi Kang, Rashid Deane, Fengfei Ding, Maosheng Xia, Jason Liew, Benjamin A. Plog, Douglas Zeppenfeld, Lulu Xie and Benjamin T. Kress and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Helen Wei

21 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impairment of paravascular clearance pathways in the aging brain

2014 1.1k citations Benjamin T. Kress, Jeffrey J. Iliff et al. Annals of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Wei United States	12	851	539	278	259	235	23	1.7k
Quan Jiang United States	14	811 1.0×	538 1.0×	605 2.2×	247 1.0×	115 0.5×	22	2.1k
Luisa Chiapparini Italy	33	759 0.9×	1.4k 2.6×	466 1.7×	260 1.0×	392 1.7×	138	3.5k
Guangliang Ding United States	28	573 0.7×	593 1.1×	448 1.6×	222 0.9×	75 0.3×	74	2.4k
Qingjiang Li United States	19	393 0.5×	414 0.8×	397 1.4×	159 0.6×	89 0.4×	37	1.6k
Donald Younkin United States	22	437 0.5×	299 0.6×	120 0.4×	450 1.7×	143 0.6×	39	2.0k
Nadia Aalling Denmark	6	898 1.1×	529 1.0×	297 1.1×	263 1.0×	207 0.9×	7	1.7k
Saburo Sakaki Japan	31	492 0.6×	1.1k 2.1×	276 1.0×	111 0.4×	284 1.2×	114	2.8k
Daniel D. Mikol United States	33	544 0.6×	666 1.2×	407 1.5×	69 0.3×	1.2k 5.1×	93	4.9k

Countries citing papers authored by Helen Wei

Since Specialization

Citations

This map shows the geographic impact of Helen Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Wei more than expected).

Fields of papers citing papers by Helen Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Wei. The network helps show where Helen Wei may publish in the future.

Co-authorship network of co-authors of Helen Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Wei. A scholar is included among the top collaborators of Helen Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Wei. Helen Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donato, Anthony J., et al.. (2024). Clinical pharmacology and tolerability of REC‐994, a redox‐cycling nitroxide compound, in randomized phase 1 dose‐finding studies. Pharmacology Research & Perspectives. 12(3). e1200–e1200. 6 indexed citations

Wei, Helen, et al.. (2022). Distal brachial artery embolization for the treatment of dialysis access steal syndrome. SHILAP Revista de lepidopterología. 2(4). 100132–100132.

Vishwanathan, Karthick, Helen Wei, Huan Liu, et al.. (2021). Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. British Journal of Clinical Pharmacology. 88(5). 2284–2296. 14 indexed citations

Alerhand, Stephen, et al.. (2020). Point-Of-Care Ultrasound Diagnosis of Medial Plantar Artery Pseudoaneurysm Secondary to Penetrating Injury. Journal of Emergency Medicine. 58(5). 781–784. 2 indexed citations

Zhou, Sitong, Michael Giannetto, Hongyi Kang, et al.. (2019). Oxygen tension–mediated erythrocyte membrane interactions regulate cerebral capillary hyperemia. Science Advances. 5(5). eaaw4466–eaaw4466. 35 indexed citations

Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519. 12 indexed citations

Witzig, T.E., Kami J. Maddocks, Sven de Vos, et al.. (2019). ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. Hematological Oncology. 37(S2). 327–328. 6 indexed citations

Owen, Roger G., Helen O. McCarthy, Simon Rule, et al.. (2018). Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 36(15_suppl). 7501–7501. 10 indexed citations

Dyer, Martin J.S., Sven de Vos, Jia Ruan, et al.. (2018). Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 36(15_suppl). 7547–7547. 12 indexed citations

10.

Telli, Melinda L., Otto Metzger, Kirsten M. Timms, et al.. (2018). Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.. Journal of Clinical Oncology. 36(15_suppl). 519–519. 24 indexed citations

11.

Gao, Fei, Donglin Zeng, Helen Wei, Xuena Wang, & Joseph G. Ibrahim. (2016). Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study. Statistics in Biosciences. 10(2). 473–489. 1 indexed citations

12.

Wei, Helen, Hongyi Kang, Sitong Zhou, et al.. (2016). Erythrocytes Are Oxygen-Sensing Regulators of the Cerebral Microcirculation. Neuron. 91(4). 851–862. 116 indexed citations

13.

McConnell, Evan, Helen Wei, Katherine M. Reitz, et al.. (2015). Cerebral microcirculatory failure after subarachnoid hemorrhage is reversed by hyaluronidase. Journal of Cerebral Blood Flow & Metabolism. 36(9). 1537–1552. 27 indexed citations

14.

Wei, Helen, Takahiro Takano, Hongyi Kang, et al.. (2015). 156 Capillary-Level Control of Cerebrovascular Tone. Neurosurgery. 62(Supplement 1). 216–217. 2 indexed citations

15.

Kress, Benjamin T., Jeffrey J. Iliff, Maosheng Xia, et al.. (2014). Impairment of paravascular clearance pathways in the aging brain. Annals of Neurology. 76(6). 845–861. 1083 indexed citations breakdown →

16.

Shirasugi, Yukari, Kiyoshi Ando, Kôji Miyazaki, et al.. (2012). An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). International Journal of Hematology. 95(6). 652–659. 33 indexed citations

17.

Bekar, Lane K., Helen Wei, & Maiken Nedergaard. (2012). The Locus Coeruleus-Norepinephrine Network Optimizes Coupling of Cerebral Blood Volume with Oxygen Demand. Journal of Cerebral Blood Flow & Metabolism. 32(12). 2135–2145. 145 indexed citations

18.

Schuette, Wolfgang, Maciej Krzakowski, Bartomeu Massutí, et al.. (2011). Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(1). 157–164. 11 indexed citations

19.

Shirasugi, Yukari, Kiyoshi Ando, Kôji Miyazaki, et al.. (2011). Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. International Journal of Hematology. 94(1). 71–80. 90 indexed citations

20.

Miyazaki, Kôji, Yukari Shirasugi, Kiyoshi Ando, et al.. (2010). Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).. Blood. 116(21). 3704–3704.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact